EGFR and colorectal carcinoma: Qualitative ctDNA analysis showed that presence of KRAS mutations in ctDNA could predict the effectiveness of targeted therapies, illustrated by an absence of clinical response to anti-EGFR therapy in stage IV CRC patients with KRAS mutations detected in pretherapeutic blood samples (61).